The Use of Antithrombotic Therapies in Reducing Synthetic Small-Diameter Vascular Graft Thrombosis

Vascular and Endovascular Surgery

Volumn 46, Issue 3, 2012, Pages 212-222

  Tatterton, Mark ^a   Wilshaw, Stacy Paul ^b   Ingham, Eileen ^b   Homer Vanniasinkam, Shervanthi ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

antiplatelet; antithrombotic therapy; Dacron; graft thrombosis; polyurethane; PTFE

Indexed keywords

7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTISTASIN; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DACRON; DEXTRO PHENYLALANYLPROLYLARGINYL CHLOROMETHYL KETONE; DIPYRIDAMOLE; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; ILOPROST; MACROGOL; N ACETYLCYSTEINYLASPARAGINYLPROLYLARGINYLGLYCYLASPARTYL(O METHYLTYROSYL)ARGINYLCYSTEINAMIDE CYCLIC 1,9 DISULFIDE; NITRIC OXIDE; POLYURETHAN; PRASUGREL; RECOMBINANT HIRUDIN; THROMBIN INHIBITOR; THROMBOMODULIN; TICAGRELOR; TISSUE FACTOR INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ARTERY INTIMA PROLIFERATION; DRUG MECHANISM; GENE THERAPY; HUMAN; NONHUMAN; PROTEIN FUNCTION; REVIEW; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION; THROMBOSIS; VASCULAR GRAFT THROMBOSIS;

ANIMALS; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; FIBRINOLYTIC AGENTS; GENE THERAPY; GRAFT OCCLUSION, VASCULAR; HUMANS; PATIENT SAFETY; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84860764575     PISSN: 15385744     EISSN: 19389116     Source Type: Journal    
DOI: 10.1177/1538574411433299     Document Type: Review

References (113)

1. Lin PH, Chen C, Bush RL, Yao Q, Lumsden A, Hanson SR.. Small-caliber heparin-coated ePTFE grafts reduce platelet deposition and neointimal hyperplasia in a baboon model. J Vasc Surg. 2004 ; 39 (6). 1322-1328 (Pubitemid 38952603)
2. Punshon G, Sales K, Vara D, Hamilton G, Seifalian A.. Assessment of the potential of progenitor stem cells extracted from human peripheral blood for seeding a novel vascular graft material. Cell Prolif. 2008 ; 41 (2). 321-335 (Pubitemid 351367498)
3. Klinkert P, Post P, Breslau P, van Bockel J.. Saphenous vein versus PTFE for above-knee femoropopliteal bypass. A review of the literature. Eur J Vasc Endovasc Surg. 2004 ; 27 (4). 357-362 (Pubitemid 38386920)
4. Sayers RD, Raptis S, Berce M, Miller JH.. Long-term results of femorotibial bypass with vein or polytetrafluroethylene. Br J Surg. 1998 ; 85 (7). 934-938 (Pubitemid 28341563)
5. Rashid S, Fuller B, Hamilton G, Seifalian A.. Tissue engineering of a hybrid bypass graft for coronary and lower limb bypass surgery. FASEB J. 2008 ; 22 (6). 2084-2089 (Pubitemid 351811484)
6. Seifalian A, Salacinski H, Tiwari A, Edwards A, Bowald S, Hamilton G.. In vivo biostability of a poly (carbonate-urea) urethane graft. Biomaterials. 2003 ; 24 (14). 2549-2557 (Pubitemid 36407669)
7. Toursarkissian B, Eisenberg PR, Abendschein DR, Rubin BG.. Thrombogenicity of small diameter prosthetic grafts: relative contributions of graft-associated thrombin and factor Xa. J Vasc Surg. 1997 ; 25 (4). 730-735 (Pubitemid 27190939)
8. Zhan F, Fan Y, Deng X.. Swirling flow created in a glass tube suppressed platelet adhesion to the surface of the tube: its implication in the design of small-caliber arterial grafts. Thromb Res. 2010 ; 125 (5). 413-418
9. Phaneuf M, Dempsey D, Bide M, Szycher M, Quist W, LoGerfo F.. Bioengineering of a novel small diameter polyurethane vascular graft with covalently bound recombinant hirudin. ASAIO J. 1998 ; 44 (5). M653 - M658
10. Fager G.. Thrombin and proliferation of vascular smooth muscle cells. Circ Res. 1995 ; 77 (4). 645-650
11. Oltrona L, Eisenberg P, Abendschein D, Rubin B.. Efficacy of local inhibition of procoagulant activity associated with small-diameter prosthetic vascular grafts. J Vasc Surg. 1996 ; 24 (4). 624-631 (Pubitemid 26346626)
12. Ariyoshi H, Okuyama M, Okahara K, et al. Expanded Polytetrafluoroethylene (ePTFE) vascular graft loses its thrombogenicity six months after implantation. Thromb Res. 1997 ; 88 (5). 427-433 (Pubitemid 28186732)
13. Haruguchi H, Teraoka S.. Intimal hyperplasia and hemodynamic factors in arterial bypass and arteriovenous grafts. A review. J Artif Organs. 2003 ; 6 (4). 227-235 (Pubitemid 38031314)
14. Giudiceandrea A, Seifalian AM, Krijgsman B, Hamilton G.. Effect of prolonged pulsatile shear stress in vitro on endothelial cell seeded PTFE and compliant polyurethane vascular grafts. Eur J Vasc Endovasc Surg. 1998 ; 15 (2). 147-154 (Pubitemid 28142858)
15. Camilleri J, Phat V, Bruneval P.. Surface healing and histiological maturation of patent polytetrafluroetylene grafts implanted in patients for up to 60 months. Arch Pathol Lab Med. 1985 ; 109 (9). 833-837 (Pubitemid 16239909)
16. Formichi M, Guidoin R, Jausseran J.. Expanded polytetrafluroethylene arterial prosthesis in humans: late pathological findings in 73 excised grafts. Ann Vasc Surg. 1988 ; 2 (1). 14-27
17. Andrade J, Hlady V.. Protein adsorption and materials biocompatibility-a tutorial review and suggested hypotheses. Adv Polymer Sci. 1986 ; 79 (1). 1-63
18. Vroman L.. Effect of adsorbed proteins on the wettability of hydrophilic and hydrophobic solids. Nature. 1962 ; 196 (4853). 476-477
19. Ikeda M, Ariyoshi H, Kambayashi J, Sakon M, Kawasaki T, Monden M.. Simultaneous digital imaging analysis of cytosolic calcium and morphological change in platelets activated by surface contact. J Cell Biochem. 1996 ; 61 (2). 292-300 (Pubitemid 26137462)
20. Spijker HT, Busscher HJ, van Oeveren W.. Influence of abciximab on the adhesion of platelets on a shielded plasma gradient prepared on polyethylene. Thromb Res. 2003 ; 108 (1). 57-62 (Pubitemid 36197663)
21. Suzuki H, Yamazaki H, Tanoue K.. Immunocytochemical aspects of platelet membrane glycoproteins and adhesive proteins during activation. Prog Histochem Cytochem. 1996 ; 30 (1). 1-106 (Pubitemid 3016197)
22. Spijker HT, Bos R, Busscher HJ, Van Kooten TG, van Oeveren W.. Platelet adhesion and activation on a shielded plasma gradient prepared on polyethylene. Biomaterials. 2002 ; 23 (3). 757-766 (Pubitemid 33108951)
23. Scharn D, Oyen W, Klemm P, Verhofstad A, van der Vliet A.. Thrombogenicity and related biological properties of heparin bonded collagen coated polyester and human umbilical vein prosthetic vascular grafts. J Surg Res. 2006 ; 134 (2). 182-189 (Pubitemid 44092813)
24. Sauvage LR, Walker MW, Berger K, et al. Current arterial prostheses: experimental evaluation by implantation in the carotid and circumflex coronary arteries of dogs. Arch Surg. 1979 ; 114 (6). 687-691 (Pubitemid 9228853)
25. d'Audiffret , Soloway P, Saadeh R. Endothelial dysfunction following thrombolysis in vitro. Eur J Vasc Endovasc Surg. 1998 ; 16 (6). 494-500 (Pubitemid 29017322)
26. Sarkar S, Sales K, Hamilton G, Seifalian A.. Addressing thrombogenicity in vascular graft construction. J Biomed Mater Res B. 2007 ; 82 (1). 100-108 (Pubitemid 47015358)
27. Motwani JG, Topol EJ.. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation. 1998 ; 97 (9). 916-931 (Pubitemid 28113931)
28. Hagemeyer C, Peter K.. Ex-vivo thrombolytic gene therapy for vein graft patency: the frontier for development of selective, localised therapeutic approaches. Thromb Haemost. 2009 ; 102 (1). 3-4
29. Kloner RA, Przyklenk K, Whittaker P.. Deleterious effects of oxygen radicals in ischaemia/reperfusion: resolved and unresolved issues. Circulation. 1989 ; 80 (5). 1115-1127 (Pubitemid 19282500)
30. Furie B, Furie BC.. Molecular and cellular biology of blood coagulation. N Engl J Med. 1992 ; 326 (12). 800-806
31. Rubin B, Toursarkissian B, Petrinec D, Ying Yang L, Eisenberg P, Abendschein DR.. Preincubation of Dacron grafts with recombinant tissue factor pathway inhibitor decreases their thrombogenicity in vivo. J Vasc Surg. 1996 ; 24 (5). 865-870 (Pubitemid 26378613)
32. Mann KG, Brummel K, Butenas S.. What is all that thrombin for?. J Thromb Haemost. 2003 ; 1 (7). 1504-1514
33. Weitz JI, Hudoba M, Massel D, Maragnore J, Hirsch J.. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990 ; 86 (2). 385-391 (Pubitemid 20271869)
34. Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP.. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood. 1988 ; 71 (21). 335-343 (Pubitemid 18089519)
35. Schachner T.. Pharmacologic inhibition of vein graft neointimal hyperplasia. J Thorac Cardiovasc Surg. 2006 ; 131 (5). 1065-1072
36. Phaneuf M, Berceli S, Bide M, Quist W, LoGerfo F.. Covalent linkage of recombinant hirudin to poly(ethylene terephthalate) (Dacron): creation of a novel antithrombin surface. Biomaterials. 1997 ; 18 (10). 755-765 (Pubitemid 27197482)
37. Wyers M, Phaneuf M, Rzucidlo E, Conteras M, LoGerfo F, Quist W.. In vivo assessment of a novel Dacron surface with covalently bound recombinant hirudin. Cardiovasc Pathol. 1999 ; 8 (3). 153-159 (Pubitemid 29290830)
38. IIa investigators, randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1996 ; 90 (4). 1631-1637
39. Heise M, Schmidmaier G, Husmann I, et al. PEG-hirudin/iloprost coating of small diameter ePTFE grafts effectively prevents pseudointima and intimal hyperplasia development. Eur J Vasc Endovasc Surg. 2006 ; 32 (4). 418-424 (Pubitemid 44348562)
40. Onder S, Kazmanli K, Kok F.. Alteration of PTFE surface to increase its blood compatability. J Biomater Sci Polym Ed. 2011 ; 22 (11). 1443-1457
41. Hanson SR, Harker LA.. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chlromethyl ketone. Proc Natl Acad Sci U S A. 1988 ; 85 (9). 3184-3188
42. Scott N, Nunes G, King S, Harker L, Hanson S.. Local delivery of an antithrombin inhibits platelet-dependent thrombosis. Circulation. 1994 ; 90 (9). 1951-1955 (Pubitemid 24320947)
43. Hanoaka T.. An experimental study of arterial graft implantation- the effects of an anti-thrombin agent, argatroban, and an antiplatelet agent, clopidogrel (SR 25990 C) on the inner capsule. Nippon Geka Gakkai Zasshi. 1994 ; 95 (10). 775-785
44. Letourneur D, Caleb BL, Castellott J.. Heparin binding, internalization, and metabolism in vascular smooth muscle cells. I: upregulation of heparin binding correlates with antiproliferative activity. J Cell Physiol. 1995 ; 165 (3). 676-686 (Pubitemid 26004326)
45. Luong-Van F, Grondahl L, Chua K, Leong K, Nurcombe V, Cool S.. Controlled release of heparin from poly (epsilon-caprolactone) electrospun fibers. Biomaterials. 2006 ; 27 (9). 2042-2050 (Pubitemid 41759498)
46. Begovac P, Thornson R, Fisher J, Hughson A, Gällhagen A.. Improvements in GORETEX vascular graft performance by carmeda bioactive surface heparin immobilization. Eur J Vasc Endovasc Surg. 2003 ; 25 (5). 432-437 (Pubitemid 36603293)
47. Bosiers M, Deloose K, Verbist V, et al. Heparin-bonded expanded polytetrafluroethylene vascular graft for femoropopliteal and femorocrural bypass grafting: 1-year results. J Vasc Surg. 2006 ; 43 (2). 313-319
48. Hugl B, Nevelsteen A, Daenens K, et al. PEPE II-a multicenter study with an end-point heparin-bonded expanded polytetrafluroethylene vascular graft for above and below knee bypass surgery: determinants of patency. J Cardiovasc Surg. 2009 ; 50 (2). 195-203
49. Pulli R, Dorigo W, Castelli P, et al. Midterm results from a multicenter registry on the treatment of infrainguinal critical limb ischemia using a heparin-bonded ePTFE graft. J Vasc Surg. 2010 ; 51 (5). 1167-1177
50. Heyligers J, Verhagen H, Rotmans J, et al. Heparin immobilization reduces the thrombogenicity of small-caliber expanded polytetrafluroethylene grafts. J Vasc Surg. 2006 ; 43 (3). 587-591 (Pubitemid 43332748)
51. Devine C, McCollum C.. Heparin-bonded Dacron or polytetrafluroethylene for femoropopliteal bypass grafting: a multicenter trial. J Vasc Surg. 2001 ; 33 (3). 533-539 (Pubitemid 32215603)
52. Devine C, McCollum C.. Heparin-bonded Dacron or polytetrafluroethylene for femoropopliteal bypass grafting: five-year results of a prospective multicenter clinical trial. J Vasc Surg. 2004 ; 40 (5). 924-931 (Pubitemid 39535222)
53. Kam P, Nethery C.. The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia. 2003 ; 58 (1). 28-35 (Pubitemid 36113325)
54. Aldenhoff Y, Koole LH.. Platelet adhesion studies on dipyridamole coated polyurethane surfaces. Eur Cell Mater. 2003 ; 5: 61-67 (Pubitemid 38957402)
55. Aldenhoff Y, Veen van der, ter Woorst J, Habets J, Poole-Warren L, Koole L.. Performance of a polyurethane vascular prosthesis carrying a dipyridamole (Persantin) coating on its luminal surface. J Biomed Mater Res. 2001 ; 54 (2). 224-233
56. Himmelfarb J, Couper L.. Dipyridamole inhibits PDGF-and bFGF-induced vascular smooth muscle cell proliferation. Kidney Int. 1997 ; 52 (6). 1671-1677 (Pubitemid 28032074)
57. Goldman M, Simpson D, Hawker R, Norcott H, McCollum C.. Aspirin and dipyridamole reduce platelet deposition on prosthetic femoro-popliteal grafts in man. Ann Surg. 1983 ; 198 (6). 713-716 (Pubitemid 14205774)
58. Pumphrey C, Cheesebro J, Dewanjee M. In vivo quantification of platelet deposition on human peripheral arterial bypass grafts using indium-111-labelled platelets. Effect of dipyridamole and aspirin. Am Journal Cardiol. 1983 ; 51 (5). 796-801 (Pubitemid 13141972)
59. Chandy T, Das G, Wilson R, Rao G.. Use of plasma glow for surface-engineering biomolecules to enhance bloodcompatability of Dacron and PTFE vascular prosthesis. Biomaterials. 2000 ; 21 (7). 699-712 (Pubitemid 30109160)
60. Walpoth B, Amonn A, Galdikas J, et al. Experimental assessment of thrombogenicity in vascular prostheses before and during prostaglandin E1 treatment. Eur J Vasc Endovasc Surg. 1993 ; 7 (5). 493-499 (Pubitemid 23266297)
61. Mazur C, Tschopp J, Faliakou E, Gould K, Diehl J, Pierschbacher M.. Selective alpha IIb beta 3 receptor blockage with peptide TP9201prevents platelet uptake on Dacron vascular grafts without significant effect on bleeding time. J Lab Clin Med. 1994 ; 124 (4). 589-599
62. Hein T, Platts S, Waitkus-Edwards K, Kuo L, Mousa S, Meininger G.. Integrin-binding peptides containing RGD produce coronary arteriolar dilatation via cyclooxygenase activation. Am J Physiol Heart Circ Physiol. 2001 ; 281 (6). H2378 - H2384
63. Lane I, Lumley P, Michael M, Peters A, McCollum C. A. specific thromboxane receptor blocking drug, AH23848, reduces platelet deposition on vascular grafts in man. Thromb Haemost. 1990 ; 64 (3). 369-373
64. Pieters H, Roodt J, Badenhorst P. Antithrombotic activity of Bay u3405, a thromboxane A2-antagonist, in patients with Dacron aortic grafts: a random controlled clinical trial. Thromb Haemost. 1993 ; 70 (6). 903-908 (Pubitemid 24008797)
65. Janssens S, Flaherty D, Nong Z, et al. Human endothelial nitric oxide gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation. 1998 ; 97 (13). 1274-1281 (Pubitemid 28169180)
66. Jerca L, Jerca O, Mancas G, Constantinescu I, Lupusoru R.. Mechanism of action and biochemical effects of Nitric Oxide (NO). J Prev Med. 2002 ; 10 (2). 35-45
67. Liu Y, Chen J, Yang Y, Wu F.. Improved blood compatability of poly(ethylene terephthalate) films modified with L-arginine. J Biomater Sci Polym Ed. 2008 ; 19 (4). 497-507 (Pubitemid 351311667)
68. Gappa-Fahlenkamp H, Lewis R.. Improved hemocompatability of poly(ethylene terephthalate) modified with various thiol-containing groups. Biomaterials. 2005 ; 26 (17). 3479-3485 (Pubitemid 40038141)
69. Duan X, Lewis R.. Improved haemocompatability of cysteine-modified polymers via endogenous nitrix oxide. Biomaterials. 2002 ; 23 (4). 1197-1203 (Pubitemid 33109051)
70. Fleser P, Nuthakki V, Malinzak L, et al. Nitric oxide-releasing biopolymers inhibit thrombus formation in a sheep model of arteriovenous bridge grafts. J Vasc Surg. 2004 ; 40 (4). 803-811 (Pubitemid 39311650)
71. Chandiwal A, Zaman F, Mast A, Hall C.. Factor Xa inhibition by immobilized recombinant tissue factor pathway inhibitor. J Biomater Sci Polym Ed. 2006 ; 17 (9). 1025-1037 (Pubitemid 44559973)
72. Raybagkar D, Patchipulusu S, Mast A, Hall C.. In vitro flow evaluation of recombinant tissue factor pathway inhibitor immobilized on collagen impregnated Dacron. ASAIO Jl. 2004 ; 50 (4). 301-305 (Pubitemid 38917874)
73. Jiao JA, Kelly A, Marzec U, et al. Inhibition of acute vascular thrombosis in chimpanzees by an anti-human tissue factor antibody targeting the factor X binding site. Thromb Haemost. 2010 ; 103 (1). 224-233
74. Gasic G, Arenas C, Gasic T, Gasic G., Coagulation factors X. Xa, and protein C as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci U S A. 1992 ; 89 (6). 2317-2320
75. Schaffer L, Davidson J, Vlasuk G, Siegl P.. Anithrombotic efficacy of recombinant tick anticoagulant peptide. a potent inhibitor of coagulation factor xa in a primate model of arterial thrombosis. Circulation. 1991 ; 84 (4). 1741-1748
76. Kotzé H, Lamprecht S, Badenhorst P, Roodt J, van Wyk V.. Transient interruption of arterial thrombosis by inhibition of Factor Xa results in long-term antithrombotic effects in baboons. Thromb Haemoss. 1997 ; 77 (6). 1137-1142 (Pubitemid 27311983)
77. Dunwoodie C, Thornberry N, Bull H, et al. Antistasin, a leech-derived inhibitor of factor Xa. J Biol Chem. 1989 ; 264 (28). 16694-16699
78. Schaffer L, Davidson J, Vlasuk G, Dunwoodie C, Siegl P.. Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons. Athero Thromb. 1992 ; 12 (8). 879-885
79. Dunwoodie C, Nutt E, Vlasuk G, Siegl P., Schaffer L.. Anticoagulant efficacy and immunogenicity of the selective factor Xa inhibitor antistasin following subcutaneous administration in the rhesus monkey. Thromb Haemost. 1992 ; 67 (3). 371-376
80. Esmon C, Owen W.. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A. 1981 ; 78 (4). 2249-2252 (Pubitemid 11119893)
81. Marlar R, Kleiss A, Griffin J.. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood. 1982 ; 59 (5). 1067-1072 (Pubitemid 12125601)
82. Gruber A, Hanson S, Kelly A, et al. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation. 1990 ; 82 (2). 578-585 (Pubitemid 20257837)
83. Gruber A, Harker L, Hanson S, Kelly A, Griffin J.. Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates. Circulation. 1991 ; 84 (6). 2454-2462
84. Li J, Singh M, Nelson P, et al. Immobilization of human thrombomodulin to expanded polytetrafluroethylene. J Surg Res. 2002 ; 105 (2). 200-208 (Pubitemid 34765328)
85. Sperling C, Koá U, Hermel G, et al. Immobilization of human thrombomodulin onto PTFE. J Mater Sci Mater Med. 1997 ; 8 (12). 789-791 (Pubitemid 28005916)
86. Vasilets V, Hermel G, Konig U, et al. Microwave CO2 plasma-initiated vapour phase graft polymerisation of acrylic acid onto polytetrafluroethylene for immobilization of human thrombomodulin. Biomaterials. 1997 ; 18 (17). 1139-1145 (Pubitemid 27346089)
87. Wong G, Li J, Hendricks G, Eslami M, Rohrer M, Cutler B.. Inhibition of experimental neointimal hyperplasia by recombinant human thrombomodulin coated ePTFE stent grafts. J Vasc Surg. 2008 ; 47 (3). 608-615 (Pubitemid 351258276)
88. Fisher C, Tew K, Appleberg M.. Prevalence and outcome of activated protein C resistance in patients after peripheral arterial bypass grafts. Cardiovasc Surg. 1999 ; 7 (5). 519-525 (Pubitemid 29349667)
89. Sampram E, Lindblad B, Dahlbäck B.. Activated protein C resistance in patients with peripheral vascular disease. J Vasc Surg. 1998 ; 28 (4). 624-629 (Pubitemid 28481215)
90. Harvey R, Kim H, Pincus J, Trooskin S, Wilcox J, Greco R.. Binding of tissue plasminogen activator to vascular grafts. Thromb Haemost. 1989 ; 61 (1). 131-136 (Pubitemid 19092683)
91. Greco R, Kim H, Donetz A, Harvey R.. Patency of a small vessel prosthesis bonded to tissue plasminogen activator and iloprost. Ann Vasc Surg. 1995 ; 9 (2). 140-145
92. Hwang C, Kim D, Hun S. In vivo evaluation of lumbrokinase, a fibrinolytic enzyme extracted from Lumbricus rubellus, in a prosthetic graft. J Cardiovasc Surg. 2002 ; 43 (6). 891-894 (Pubitemid 36040828)
93. Kitamoto Y, Tomita M, Kiyami S, et al. Antithrombotic mechanisms of urokinase immobilized polyurethane. Thromb Haemost. 1991 ; 65 (1). 73-76
94. Ryu G, Park S, Kim M, Han D, Kim Y, Min B.. Antithrombogenicity of lumbrokinase-immobilized polyurethane. J Biomed Mater Res. 1994 ; 28 (9). 1069-1077 (Pubitemid 24274849)
95. van Zyl W, Pretorius G, Hartmann M, Kotzé H.. Production of a recombinant antithrombotic and fibrinolytic protein. PLATSAK, in Escherichia coli. Thromb Res. 1997 ; 88 (5). 419-426 (Pubitemid 28186731)
96. van Zyl W, Pretorius G, Lamprecht S, Roodt J, Kotzé H.. PLATSAK, a potent anithrombotic and fibrinolytic protein, inhibits arterial and venous thrombosis in a baboon model. Thromb Res. 2000 ; 98 (5). 435-443 (Pubitemid 30319316)
97. Clowes A.. Control of neointimal hyperplasia in ePTFE grafts. J Vasc Surg. 1997 ; 25 (6). 1100-1101
98. Meinhart J, Deutsch M, Fischlein T, Howanietz N, Froschl A, Zilla P.. Clinical autologous in vitro endothelialization of 153 infrainguinal ePTFE grafts. Annals Thorac Surg. 2001 ; 71 (5 suppl). S327 - S331
99. Zilla P, Deutsch M, Meinhart J, et al. Clinical in vitro endothelialization of femoropopliteal bypass grafts: an actuarial follow-up over three years. J Vasc Surg. 1994 ; 19 (3). 540-548 (Pubitemid 24093990)
100. Sarkar S, Burriesci G, Wojcik A, Aresti N, Hamilton G, Seifalian A.. Manufacture of small calibre quadruple lamina vascular bypass grafts using a novel automated extrusion-phase-inversion method and nanocomposite polymer. J Biomech. 2009 ; 42 (6). 722-730
101. Deutsch M, Meinhart J, Fischlein T, Preiss P, Zilla P.. Clinical autologous in vitro endothelialization of infrainguinal ePTFE grafts in 100 patients: a 9-year experience. Surgery. 1999 ; 126 (5). 847-855 (Pubitemid 29523323)
102. Deutsch M, Meinhart J, Vesely M. In vitro endothelialization of expanded polytetrafluroethylene grafts: a clinical case report after 41 months implantation. J Vasc Surg. 1997 ; 25 (4). 757-763 (Pubitemid 27190944)
103. Meinhart J, Deutsch M, Zilla P.. Eight years of clinical endothelial cell transplantation. Closing the gap between prosthetic grafts and vein grafts. ASAIO J. 1997 ; 43 (5). M515 - M521
104. Quiniones M, Leor J, Kloner R, et al. Avoidance of immune response prolongs expression of genes delivered to the adult rat myocardium by replication-defective adenovirus. Circulation. 1996 ; 94 (6). 1394-1401 (Pubitemid 26307271)
105. Dichek D, Anderson J, Kelly A, Hanson S, Harker L.. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Circulation. 1996 ; 93 (2). 301-309 (Pubitemid 26031489)
106. Dunn P, Newman K, Jones M, et al. Seeding of vascular grafts with genetically modified endothelial cells. Secretion of recombinant TPA results in decreased seeded cell retention in vitro and in vivo. Circulation. 1996 ; 93 (7). 1439-1446 (Pubitemid 26099356)
107. Huber T, Welling T, Sarkar R, Messina L, Stanley J.. Effects of retroviral-mediated tissue plasminogen activated gene transfer and expression on adherence and proliferation of canine endothelial cells seeded onto expanded polytetrafluroethylene. J Vasc Surg. 1995 ; 22 (6). 795-803 (Pubitemid 26013938)
108. Kimura H, Sakata Y, Hamada H. In vivo retention of endothelial cells adenovirally transduced with tissue-type plasminogen activator and seeded onto expanded polytetrafluroethylene. J Vasc Surg. 2000 ; 32 (2). 353-363 (Pubitemid 30644950)
109. Falk J, Townsend L, Vogel L, Boyer M, Olt S, Wease G.. Improved adherence of genetically modified endothelial cells to small-diameter expanded polytetrafluroethylene grafts in a canine model. J Vasc Surg. 1998 ; 27 (5). 902-908
110. Dardik A, Liu A, Ballermann B.. Chronic in vitro shear stress stimulates endothelial cell retention on prosthetic vascular grafts and reduces subsequent in vivo neointimal thickness. J Vasc Surg. 1999 ; 29 (1). 157-167 (Pubitemid 29035943)
111. Byrom M, Bannon P, White G, Ng M.. Animal models for the assessment of novel vascular conduits. J Vasc Surg. 2010 ; 52 (1). 176-195
112. Chen C, Lumsden A, Hanson SR.. Local infusion of heparin reduces anastomotic neointimal hyperplasia in aortoiliac expanded polytetrafluoroethylene grafts in baboons. J Vasc Surg. 2000 ; 31 (2). 354-363 (Pubitemid 30100044)
113. Konya A, Wright K, Gounis M, Kandarpa K. Sourcebook of Models for Biomedical Research. Conn PM, ed. Totowa, NJ: Humana Press ; 2008: 369-384.